The New Trial by Merck & Co Inc and Moderna Inc’s Impact on Moderna Stock
News recently surfaced on clinicaltrials.gov that Merck & Co Inc posted a new trial involving Moderna Inc’s V940, an individualized neoantigen therapy, combined with pembrolizumab for locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC).
The trial consists of three arms, aiming to evaluate the safety and efficacy of V940 in combination with pembrolizumab as neoadjuvant and adjuvant therapy for participants with resectable LA cSCC compared to standard-of-care SOC only.
With Phase 3 expansion potentially on the horizon, the trial signifies a significant investment in the program, indicating strong confidence in the project’s success.
This trial is crucial as it explores both neo- and adjuvant therapy, addressing a rising concern with cSCC, a more aggressive type of skin cancer, accounting for a notable percentage of malignant cutaneous melanoma cases.
Analysts at Jefferies and RBC Capital emphasize the pivotal nature of this trial, highlighting the potential impact on the market and the growing prevalence of cSCC cases in the U.S.
Price Action: Moderna Inc’s shares surged by 8.96% to reach $112.26 as investors took notice of the promising developments on Monday.
